NASDAQ:INSM • US4576693075
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INSMED INC (INSM).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-24 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-02-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-30 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-28 | Barclays | Initiate | Overweight |
| 2026-01-23 | Roth Capital | Initiate | Buy |
| 2026-01-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-06 | UBS | Maintains | Buy -> Buy |
| 2025-12-18 | TD Cowen | Maintains | Buy -> Buy |
| 2025-12-18 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-18 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-18 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-16 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-12-16 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-15 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-11 | TD Cowen | Maintains | Buy -> Buy |
| 2025-12-01 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-11-20 | TD Cowen | Maintains | Buy -> Buy |
| 2025-10-31 | UBS | Maintains | Buy -> Buy |
| 2025-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-31 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-31 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-27 | B of A Securities | Maintains | Buy -> Buy |
| 2025-10-14 | UBS | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 305.208M 24.37% | 363.707M 19.17% | 606.423M 66.73% | 1.628B 168.46% | 2.702B 65.97% | 3.921B 45.11% | 5.287B 34.84% | 6.606B 24.95% | 8.27B 25.19% | 9.902B 19.73% | 11.433B 15.46% | |
| EBITDA YoY % growth | -667.638M -43.33% | -772.845M -15.76% | -975.614M -26.24% | -669.888M 31.34% | 24.598M 103.67% | 763.68M 3,004.64% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -680.929M -42.42% | -786.57M -15.51% | -994.776M -26.47% | -584.019M 41.29% | 172.85M 129.60% | 1.137B 557.80% | 2.083B 83.20% | 2.909B 39.65% | 4.172B 43.42% | 5.469B 31.09% | 6.596B 20.61% | |
| Operating Margin | -223.10% | -216.26% | -164.04% | -35.87% | 6.40% | 29.00% | 39.40% | 44.04% | 50.45% | 55.23% | 57.69% | |
| EPS YoY % growth | -5.34 -36.92% | -5.59 -4.68% | -6.41 -14.67% | -2.93 54.28% | 0.48 116.48% | 4.02 731.70% | 7.84 95.17% | 10.72 36.72% | 15.03 40.18% | 18.88 25.65% | 22.78 20.64% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.00 29.27% | -0.82 51.55% | -0.82 53.20% | -0.85 45.03% | -0.99 1.50% | -0.77 7.12% | -0.42 48.94% | -0.14 83.13% |
| Revenue Q2Q % growth | 304.05M 227.56% | 381.7M 255.35% | 348.97M 145.16% | 358.44M 35.85% | 416.08M 36.85% | 483.96M 26.79% | 587.6M 68.38% | 672.64M 87.66% |
| EBITDA Q2Q % growth | -194.499M 13.94% | -162.343M 33.91% | -137.465M 44.67% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -206.595M 10.11% | -166.193M 34.54% | -184.037M 29.58% | -204.673M 18.03% | N/A | N/A | N/A | N/A |
All data in USD
26 analysts have analysed INSM and the average price target is 216.28 USD. This implies a price increase of 54.34% is expected in the next year compared to the current price of 140.13.
INSMED INC (INSM) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of INSMED INC (INSM) is -1 USD and the consensus revenue estimate is 304.05M USD.
The consensus rating for INSMED INC (INSM) is 85.3846 / 100 . This indicates that analysts generally have a positive outlook on the stock.